Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

4122 Background: A recent systematic review, based largely on non-randomised, retrospective studies, suggested that K-ras mutations may identify patients who do not benefit from cetuximab and panitumumab. In support of this hypothesis, four RCTs have shown a lack of benefit or detriment of EGFR-targeted therapy in patients with K-ras mutations. In this systematic review, we aim to provide a comprehensive and unbiased synthesis of the effects of these MAbs, by K-ras status, in both chemotherapy (CT) responsive and CT-refractory ACRC patients. METHODS: A systematic review and meta-analysis of all relevant RCTs is ongoing. Progression-free survival (PFS) is the primary outcome, with survival and response as secondary outcomes. We have conducted systematic searches of a number of trial sources. Data on trial and patient characteristics, and outcome have been extracted from trial reports or presentations, for all patients and for K-ras wild-type and mutant cohorts. Where possible, trial results were pooled in a stratified-by- trial meta-analysis. For unpublished RCTs, or those published with insufficient information, we are seeking further data. RESULTS: Searches identified 15 eligible RCTs in CT-responsive patients, 12 using cetuximab and 3 panitumumab. Three of these trials included bevacizumab in both arms. PFS has only been reported for 6 RCTs, so further data are needed to ensure an unbiased analysis. Only two RCTs were identified in CT-refractory patients. Together, these showed an improvement in PFS with anti-EGFR MAb (HR=0.61, 95% CI 0.49-0.76, p<0.0001). Furthermore, there was a significant difference in the size of the effect by K-ras status (interaction p<0.0001), with an improvement in PFS for patients with wild type K-ras, (HR=0.43, 95% CI 0.35-0.52, p<0.0001), but not those with mutant K-ras (HR=0.99 95% CI 0.80-1.23, p=0.93). CONCLUSIONS: These preliminary results suggest that the benefits of anti-EGFR MAb therapy, at least in CT-refractory patients, are confined to those with wild type K-ras. Results for CT-responsive patients, and updated analyses for CT-refractory patients, will be presented. [Table: see text].

Type

Journal article

Journal

J Clin Oncol

Publication Date

20/05/2009

Volume

27